

CONTENTS

1. Commentary	v1
D. Goldsmith	
2. The protein science of biosimilars	v4
M. Kuhlmann and A. Covic	
3. Immunogenicity of biopharmaceuticals	v9
M. Kessler, D. Goldsmith and H. Schellekens	
4. Comparative testing and pharmacovigilance of biosimilars	v13
F. Locatelli and S. Roger	
5. European regulatory guidelines for biosimilars	v17
A. Wiecek and A. Mikhail	

All reasonable precautions have been taken by the authors, editors, and publishers to verify drug names and doses, the results of experimental work, and the clinical findings published in this Supplement. The opinions expressed are those of the authors, and not necessarily those of the editors or publishers. The ultimate responsibility for the use and dosage of drugs mentioned in this Supplement and in the interpretation of published material lies with the medical practitioners and the editors and publishers can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

Please visit the Journal's World Wide Web site at www.ndt.oxfordjournals.org